Logo.png
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
30 nov. 2022 14h08 HE | Biofrontera Inc.
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Logo.png
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
21 nov. 2022 08h48 HE | Biofrontera Inc.
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Logo.png
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
14 nov. 2022 08h45 HE | Biofrontera Inc.
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the...
Logo.png
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
10 nov. 2022 11h52 HE | Biofrontera Inc.
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
Logo.png
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
08 nov. 2022 16h45 HE | Biofrontera Inc.
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Logo.png
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
24 oct. 2022 07h45 HE | Biofrontera Inc.
WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the...
Logo.png
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
18 oct. 2022 10h30 HE | Biofrontera Inc.
Four Posters Highlighting Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be Presented WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
Logo.png
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
29 sept. 2022 10h04 HE | Biofrontera Inc.
WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Logo.png
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
13 sept. 2022 08h30 HE | Biofrontera Inc.
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the...
Logo.png
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
06 sept. 2022 10h31 HE | Biofrontera Inc.
Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols WOBURN, Mass., Sept. 06, 2022 (GLOBE...